Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine

Over the past decade, patients with advanced non-small-cell lung cancer (NSCLC) have witnessed substantial advances in regards to therapeutic alternatives. Among newly developed agents, angiogenesis inhibitors were extensively tested in different settings and have produced some favorable outcomes de...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabchi, Samer, Blais, Normand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372785/
https://www.ncbi.nlm.nih.gov/pubmed/28424759
http://dx.doi.org/10.3389/fonc.2017.00052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372785/
https://www.ncbi.nlm.nih.gov/pubmed/28424759
http://dx.doi.org/10.3389/fonc.2017.00052

Ejemplares similares